- IFW



Docket No. PRD2121USPCT

THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicants: Dominique Mabire

Serial No.: 10/596,086

Art Unit:

Filed

: November 18, 2004

Examiner:

For

: 6-SUBSTITUTED 2-QUINOLINONES AND 2-QUINOXALINONES

AS POLY(ADP-RIBOSE)POLYMERASE INHIBITORS

I hereby certify that this correspondence is being deposited with the United States Postal Service as first class mail in an envelope addressed to: Commissioner For Patents, P.O. Box 1450, Alexandria, VA 22313-1450 on

October 30, 2006
(Date of Deposit)

Alana G. Kriegsman (Name of applicant, assignee, or Registered Representative)

/Alana G. Kriegsman/

(Signature)

October 30, 2006

(Date of Signature)

Mail Stop: Patent Application Commissioner for Patents P.O. Box 1450 Alexandria, VA 22313-1450

INFORMATION DISCLOSURE STATEMENT

Dear Sir:

Pursuant to 37 C.F.R. §1.56 and in accordance with 37 C.F.R. §§1.97-1.98, information relating to the above-identified application is hereby disclosed. Inclusion of information in this statement is not to be construed as an admission that this information is material as that term is defined in 37 C.F.R. §1.56(b).

Applicant(s) reserve(s) the right to establish the patentability of the claimed invention over any of the information provided herewith, and/or to prove that this information may not be prior art, and/or to prove that this

information may not be enabling for the teachings purportedly offered.

This statement should not be construed as a representation that a search has been made, or that information more material to the examination of the present patent application does not exist.

Disclosure Statement is being filed either within three months of the filing date of the above-identified national application (other than a continued prosecution application under \$1.53(d)), within three months of the date of entry into the national stage of the above identified application as set forth in \$1.491, or before the mailing date of a first Office Action on the merits of the above-identified application, or before the mailing date of a first Office Action after the filing of a request for continued examination under \$1.114, no additional fee is required.

In a	ccordance with §1.129(a), this Information
Disclosure Stat	tement is being filed in connection with \square the
first or 🗌 seco	ond After Final Submission, therefore:
	Statement in Accordance with §1.97(e)
	(attached); or
	Please charge Deposit Account No. 10-
	0750/ / the fee of $$180.00$ as set forth
	in §1.17(p).

In accordance with §1.97(c), this Information Disclosure Statement is being filed after the period set forth in §1.97(b) above but before the mailing date of either a Final Action under §1.113 or a Notice of Allowance under §1.311, or an action that otherwise closes prosecution and that it is accompanied by one of:

		Statement in Accordance with §1.97(e)
		(attached); or
		Please charge Deposit Account No. 10-
		0750/ / the fee of $$180.00$ as set forth
		in §1.17(p).
	In ac	cordance with §1.97(d), this Information
Disclosure	Stat	ement is being filed after the mailing date of
either a F	'inal	Action under §1.113 or a Notice of Allowance
under §1.	311 b	ut before the payment of the Issue Fee.
Applicant(s) he	reby petition(s) for consideration of this
Informatio	n Dis	closure Statement. Included are: Statement in
Accordance	with	§1.97(e) as set forth below and the fee of
\$180.00 as	set	forth in §1.17(p).
\boxtimes	~	s of each of the references listed on the
attached F	orm P	TO-1449 are enclosed herewith.
П	Copie	s of references listed on the attached Form PTO
 1449 are e	-	ed herewith EXCEPT THAT:
		In view of the voluminous nature of references
	_	[list as appropriate], and the likelihood that
		these references are available to the Examiner,
		copies are not enclosed herewith.
		If any of the foregoing publications are not
		available to the Examiner, Applicant will
		endeavor to supply copies at the Examiner's
		request.
\boxtimes	Copie	es of only foreign patent documents and non-
 patent lit	eratu	re are enclosed in accordance with 37 CFR 1.98
(a)(2).		

· · · ·

There are no listed references which are not in the \boxtimes English language. The relevance of those listed references which are not in the English language is as follows: Attached are copies of search report(s) from \boxtimes corresponding patent application(s), which are listed on the attached Submission Under MPEP 609 D. Attached are the following non-published pending patent applications which may be deemed relevant, which are listed on the attached Submission Under MPEP 609 D. Please charge any deficiency or credit any overpayment to Deposit Account No. 10-0750/PRD2121USPCT/AGK. This form is submitted in triplicate. Respectfully submitted, /Alana G. Kriegsman/ Alana G. Kriegsman Req. No. 41,747 Attorney for Applicants Johnson & Johnson One Johnson & Johnson Plaza

New Brunswick, NJ 08933-7003 (732) 524-1495 DATED: October 30, 2006



PTO/SB/08A (08-00)
Approved for use through 10/31/2002. OMB 0651-0031
U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

Substitute for form 1449A/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary)
Sheet 1 of 2

a conection of information unless it displays a	Valid Civid Control Hamber.
Application Number	10/596,086
Filing Date	11/18/2004
First Named Inventor	Dominique Mabire
Group Art Unit	
Examiner Name	
Attorney Docket Number	PRD2121USPCT

U.S. PATENT DOCUMENTS U.S. Patent Document Date of Publication Pages, Columns, Lines, Name of Patentee or Applicant Kind Code² Examiner Cite of Cited Document where relevant passages or of Cited Document Initials relevant figures appear (if known) No.1 Number mm-dd-yyyy 5177075 Warner-Lambert Company 01-05-1993

FOREIGN PATENT DOCUMENTS

		Foreign	Patent Docum	ent	Name of Patentee or	Date of Publication of Cited Document	Pages, Columns, Lines, where relevant	
Examiner Initials	Cite No.1	Office ³	Number ⁴	KindCode ⁵	Applicant of Cited Document	mm-dd-yyyy	passages or relevant figures appear	T ⁶
		EP	0371564	B1	Janssen Pharmaceutica, N.v.	06-06-1990		
						-		

Examiner	Date	
Signature	Considered	

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U. S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS, SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450

^{*}EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number. 2 See attached Kinds of U.S. Patent Documents. 3 Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). 4 For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. 5 Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. 6 Applicant is to place a check mark here if English language Translation is attached.

PTO/SB/08A (08-00)

Approved for use through 10/31/2002. OMB 0651-0031
U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

U.S. Patent and Trademark Unice: U.S. DEPARTMENT OF COMMERCE U.S. Patent and Trademark Unice: U.S. DEPARTMENT OF COMMERCE U.S. Patent and Trademark Unice: U.S. DEPARTMENT OF COMMERCE U.S. Patent and Trademark Unice: U.S. DEPARTMENT OF COMMERCE U.S. Patent and Trademark Unice: U.S. DEPARTMENT OF COMMERCE U.S. Patent and Trademark Unice: U.S. DEPARTMENT OF COMMERCE U.S. Patent and Trademark Unice: U.S. DEPARTMENT OF COMMERCE U.S. Patent and Trademark Unice: U.S. DEPARTMENT OF COMMERCE U.S. Patent and Trademark Unice: U.S. DEPARTMENT OF COMMERCE U.S. Patent and Trademark Unice: U.S. DEPARTMENT OF COMMERCE U.S. Patent and Trademark Unice: U.S. DEPARTMENT OF COMMERCE U.S. DEPARTMENT OF COMMERCE U.S. DEPARTMENT OF COMMERCE U.S. Patent and Trademark Unice: U.S. DEPARTMENT OF COMMERCE U.S. Patent and Trademark Unice: U.S. DEPARTMENT OF COMMERCE U.S. Patent and Trademark Unice: U.S. DEPARTMENT OF COMMERCE U.S. DEPARTMENT OF U.S. DEPARTMENT OF

Substitute for form 1449A/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary)
Sheet 2 of 2

a concessor or intermedien amous it displays a	Tana Ome Control Hambor.
Application Number	10/596,086
Filing Date	11/18/2004
First Named Inventor	Dominique Mabire
Group Art Unit	
Examiner Name	
Attorney Docket Number	PRD2121USPCT

		OTHER PRIOR ART - NON PATENT LITERATURE DOCUMENTS	
Examiner's Initials*	Cite No.1	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published	T²
		KULCSAR et al., "Synthesis and Study of New 4-Quinazolinone Inhibitors of the DNA Repair Enzyme Poly (ADP-ribsose) Polymerase (PARP)", ARKIVOC, XX,XX, June 11, 2003, pages 121-123, Vol. 2003, No. PART V, XP002291367.	
		LI et al., "PARP Inhibitors", IDrugs, 2001, pages 804-812, Vol. 4, No. 7, Current Drugs Ltd., GB.	
		WELTIN et al., "Effect of 6(5-Phenanthridinone, an Inhibitor of Poly(ADP-ribose) Polymerase, on Cultured Tumor Cells", Oncology Research, 1994, pages 399-403, Vo.I. 6, No. 9, El Servier Ltd., USA.	
-			
_			
	_		

Examiner	Date	
Signature	Considered_	

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U. S. Patent and Trademark Office, Washington, DC 20231.

DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA

22313-1450.

^{*}EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number. 2 Applicant is to place a check mark here if English language Translation is attached.



SUBMISSION UNDER MPEP 609 D

Page 1 of 1

Ī	Application Number	10/596,086
	Filing Date	11/18/2004
	First Named Inventor	Dominique Mabire
	Group Art Unit	
	Examiner Name	
	Attorney Docket Number	PRD2121USPCT

		U.S. PA	TENT DOCUMENTS		
			U.S. Patent Docume	ent	
Examiner Initials			Number	Kind Code ² (if known)	Pages, Columns, Lines, where relevant passages or relevant figures appear
		-			
		"			

FOREIGN PATENT DOCUMENTS Foreign Patent Document Pages, Columns, Lines, where relevant passages or relevant figures appear Name of Patentee or Cite Examiner Applicant of Cited Document KindCode⁵ Office³ Number⁴ Initials No.1 OTHER PRIOR ART - NON PATENT LITERATURE DOCUMENTS Include name of the author (in CAPITOL LETTERS), title of the article (when appropriate), T^2 title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published Cite No.1 Examiner 's Initials* PCT Intl. Search Report, PCT/EP2004/013164, March 14, 2005.

Examiner	Date	
Signature	Considered	